Aprea Therapeutics Inc is a biotechnology business based in the US. Aprea Therapeutics shares (APRE) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.78 |
|---|---|
| 52-week range | $0.62 - $5.89 |
| 50-day moving average | $1.02 |
| 200-day moving average | $2.71 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.775 from 2022-07-01
| 1 week (2022-06-27) | -9.46% |
|---|---|
| 1 month (2022-06-01) | 1.31% |
| 3 months (2022-04-01) | -58.11% |
| 6 months (2022-01-04) | -74.76% |
| 1 year (2021-07-02) | -85.27% |
|---|---|
| 2 years (2020-07-02) | -97.88% |
| 3 years (2019-06-30) | N/A |
| 5 years (2017-06-30) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -33.78% |
| Return on equity TTM | -62.79% |
| Profit margin | 0% |
| Book value | $1.98 |
| Market capitalisation | $17.5 million |
TTM: trailing 12 months
We're not expecting Aprea Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aprea Therapeutics's shares have ranged in value from as little as $0.62 up to $5.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aprea Therapeutics's is 0.1664. This would suggest that Aprea Therapeutics's shares are less volatile than average (for this exchange).
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.